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Rabies vaccines based on live attenuated rabies viruses or recombinant pox viruses expressing the rabies virus (RV) glycoprotein (G) hold the
greatest promise of safety and efficacy, particularly for oral immunization of wildlife. However, while these vaccines induce protective immunity
in foxes, they are less effective in other animals, and safety concerns have been raised for some of these vaccines. Because canine adenovirus 2
(CAV2) is licensed for use as a live vaccine for dogs and has an excellent efficacy and safety record, we used this virus as an expression vector for
the RVG. The recombinant CAV2-RV G produces virus titers similar to those produced by wild-type CAV2, indicating that the RVG gene does not
affect virus replication. Comparison of RVG expressed by CAV2-RV G with that of vaccinia-RV G recombinant virus (V-RG) revealed similar
amounts of RV G on the cell surface. A single intramuscular or intranasal immunization of mice with CAV2-RVG induced protective immunity in
a dose-dependent manner, with no clinical signs or discomfort from the virus infection regardless of the route of administration or the amount of
virus.
© 2006 Elsevier Inc. All rights reserved.Keywords: Rabies virus; Rabies virus glycoprotein (RVG); Rabies recombinant virus vaccines; Canine adenovirus 2 (CAV2); Canine adenovirus 2-rabies virus
glycoprotein recombinant (CAV2-RV G) vaccine; Oral immunizationIntroduction
Rabies is the 10th most common lethal infectious disease
causing approximately 60,000 annual human deaths worldwide
(Martinez, 2000). In most developing countries, stray dogs
represent the major reservoir of rabies virus, whereas wildlife is
important in many developed countries (Meslin et al., 1994).
Parenteral immunization of dogs with killed rabies virus (RV)
vaccines, which is the most effective method to control dog
rabies, is very difficult to perform with stray dogs and unrealistic
for wildlife. An alternative to parenteral immunization with
killed RV vaccine is oral immunization with live recombinant
viruses expressing the RV G or modified-live rabies viruses
(CDC, 2000; Winkler and Bogel, 1992). Indeed, vaccinations
using vaccinia-RVG recombinant virus (V-RG) or modified-live
rabies viruses, such as the Ellen–Rockitniki–Abelseth strain⁎ Corresponding author.
E-mail address: bernhard.dietzschold@jefferson.edu (B. Dietzschold).
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doi:10.1016/j.virol.2006.07.037(ERA), the Street–Alabama–Dufferin strain (SADB19), and the
SAD Avirulent Gif strains (SAG-1 and SAG-2), have resulted in
almost complete elimination of vulpine rabies inWestern Europe
(Aubert et al., 1994). However, while these vaccines induce
protective immunity in foxes (Aubert et al., 1994) and raccoons
(Rupprecht et al., 1986), neither V-RG nor first-generation SAD-
and ERA-based modified live rabies vaccines work well in dogs
or skunks (Rupprecht et al., 1990; Tolson et al., 1987, 1988).
Moreover, the V-RG vaccine may be associated with environ-
mental or public health limitations (Rupprecht et al., 2001).
Clearly, there is a need for additional safe and potent rabies
vaccines for wild animals and stray dogs.
Because adenoviruses replicate on mucosal surfaces, they
represent appropriate vectors that can be administered both
orally and intranasally (Fischer et al., 2002). Replication-
competent and replication-deficient human recombinant ade-
noviruses expressing RVG have been developed (Prevec et al.,
1990) and tested in different animal models. Skunks and foxes
vaccinated per os with a replication-competent recombinant
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infection (Charlton et al., 1992), indicating the potential of
recombinant adenoviruses as oral vaccines for wildlife. Live
modified canine adenovirus type 2 (CAV2),which is alreadyused
worldwide for the routine vaccination of dogs against both CAV1
andCAV2and has an excellent safety record (Fischer et al., 2002;
Appel et al., 1975), represents an almost ideal vaccine vector for
immunization of carnivores against rabies. Although this vaccine
is usually administered subcutaneously, it is also effective when
given orally (Baer et al., 1989). Whereas CAV2 did not spread
after parenteral inoculation (Appel et al., 1975), oral–nasal
administration resulted in replication of this virus in surface
epithelium, which seems to be essential for oral immunization
(Appel et al., 1975). Skunks developed only mild respiratory
signs and recovered completely after 1 week following oral
administration of CAV2 (Sumner et al., 1988).
We have constructed a recombinant CAV2 that expresses the
RVG under the control of the human cytomegalovirus (CMV)
early promoter/enhancer and assessed the safety and protective
activity of the CAV2-RV G vaccine in mice. Here we show that
CAV2-RV G-infected MDCK cells express RV G protein on the
cell surface at levels similar to those on MDCK cells infected
with V-RG, which is currently one of the gold standards for oral
rabies vaccines. CAV2-RV G administered intramuscularly
(i.m.) or intranasally (i.n.) into mice resulted in the induction
of RV-neutralizing antibody and protection against a lethal RV
challenge infection in a dose-dependent manner.Results
Construction and selection of a recombinant CAV2-RV G virus
Neither CAV2 nor CAV2-RV G induces a distinct
cytopathic effect in tissue culture, obviating the selection
and purification of recombinant CAV2-RV G virus by standard
plaque selection. Thus, as proof-of-concept, we first con-
structed CAV2 containing green fluorescent protein as a
reporter gene (CAV2-GFP). Foci of CAV2-GFP-infected cells
were easily identified by GFP expression and picked up. After
cloning the CAV2-GFP construct, we transfected MDCK cells
with CAV2-GFP DNA together with the DNA containing the
RVG expression cassette (Fig. 1). Recombinant CAV2-RV G
virus was cloned, selected, and characterized using Southern
blotting and PCR analysis. PCR analysis revealed the presence
of both the GFP and the RV G genes in virus preparations
recovered after the 1st and 12th cloning cycles. Only the RV
G gene was detectable in the virus population that was
recovered after the 26th cloning cycle (Fig. 2). Furthermore,
MDCK cells infected with the virus recovered from the first
cloning cycle showed massive GFP fluorescence, but only a
few fluorescent foci were detected after incubation with anti-
RV G-specific rabbit IgG followed by incubation with Alexa
Fluor 610-labeled anti-rabbit IgG. By contrast, strong RV G
immunostaining but no GFP fluorescence was seen in cells
infected with virus recovered from the 26th cloning cycle
(data not shown).Growth of CAV2-RV G in vitro
A potential problem associated with any recombinant
adenovirus carrying foreign genes is that the introduction of
an extra gene into the viral genome affects the replication
efficiency of the virus. However, comparison of the time
courses of virus production in MDCK cells infected with
CAV2 or CAV2-RV G revealed no differences (Fig. 3),
indicating that the insertion of a RV G gene does not affect
virus replication.Expression of the RV G in CAV2-RV G-infected MDCK cells
Fluorescence microscopy was used to determine whether the
RVG is correctly expressed by the CAV2 vector. Fluorescence
microscopy revealed CAV2 antigen in both CAV2- and CAV2-
RVG-infected MDCK cells (Figs. 4C, F) but RV G-specific
immunostaining only in CAV2-RVG-infected MDCK cells
(Fig. 4B) and not in CAV2-infected MDCK cells (Fig. 4E).
Whereas CAV2-antigen staining was localized mainly within
the cell (Figs. 4C, F), RV G was predominantly detected on the
cell surface membrane (Fig. 4B), indicating that this protein is
correctly processed and most likely retains its antigenic
structure.
Immunoprecipitation analysis comparing the levels of RV G
expressed by the CAV2 vector with the levels expressed by V-
RG indicated similar expression levels in CAV2-RV G-infected
MDCK cells and in V-RG-infected MDCK cells (Fig. 5). Flow
cytometry to measure the relative cell surface expression of RVG
on MDCK cells at 48 h p.i. also revealed comparable surface
expression in CAV2-RVG-infected cells and in V-RG-infected
cells (Fig. 6). Thus, based on the RVG expression levels, the
CAV2-RVGvaccine is expected to have a potency comparable to
that of the V-RG vaccine.Immunogenicity and pathogenicity of CAV2-RV G in mice
To assess the immunogenicity of CAV2-RVG, mice were
inoculated once i.m. or i.n. with serial dilutions of CAV2-RV G.
While mice immunized i.m. with 108 infectious particles
produced a VNA GMT of 47.5 IU, the VNA titer in mice
immunized with 107 and 106 FFU decreased in a dose-
dependent manner resulting in VNA titers of 6.7 and 0.3 IU,
respectively (Table 1). Similarly, dose-dependent differences in
VNA titers were also seen after i.n. immunization (Table 1).
Note that mice immunized with107 FFU i.n. developed a VNA
GMTof 12.8, indicating that i.n. administration of the virus is as
effective as i.m. administration.
None of the mice that received CAV2-RVG by the i.m. or the
i.n. route developed clinical signs or showed loss of body
weight within the 4-week observation period, regardless of the
amount of virus administered.
The VNA data were paralleled by the results of a virus
challenge experiment that revealed 90% protection of mice
vaccinated i.m. with 108 or 107 FFU of CAV2-RV G and 70%
Fig. 1. Schematic representation of the construction of a full-length cDNA clone of CAV2-RV G. A GFP expression cassette was constructed consisting of 3′ and
5′ flanking sequences of the E3 region of CAV2 DNA, sequences encoding the CMV promoter and GFP, and a poly-A sequence. This cassette was transfected
together with CAV2 DNA into MDCK cells, resulting in recombinant CAV2-GFP. The GFP gene of CAV2-GFP was then replaced with the RV G gene by
cotransfection of MDCK cells with CAV2-GFP DNA and a RV G expression cassette, resulting in CAV2-RV G.
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G, respectively, and challenged i.m. with 10 LD50 of CVS-N2c
(Table 1).
Discussion
RV vaccines based on recombinant viruses hold the
promise of safety and efficacy (Dietzschold et al., 2003). In
the past two decades, several viruses have been investigated
for their ability to express RV proteins and to induce
protective immunity (reviewed in Dietzschold et al., 2003).
Besides attenuated RVs, the V-RG is probably the best studied
and most extensively used vaccine. However, while V-RG
given to a large variety of warm-blooded animals by different
routes has proven to be an extremely effective RV vaccine
(Brochier et al., 1991; Wiktor et al., 1984b, Tolson et al.,Fig. 2. PCR analysis of recombinant CAV2 DNA isolated from virus recovered
after the 1st, 12th, and 26th cloning cycle. To identify the presence of the GFP
gene and RV G gene, DNAwas isolated from the supernatant of infected MDCK
cells and subjected to PCR using RV G- or GFP-specific primers.1987), it does not work well in skunks or dogs (Rupprecht et
al., 1990; Tolson et al., 1987, 1988). Furthermore, a recent
incident raised concerns regarding the safety of V-RG
(Rupprecht et al., 2001). These observations underline the
need for safer live RV vaccines. Because the Manhattan strain
of CAV2, which is used as an effective modified live vaccine
for dogs, has been safe (Fischer et al., 2002), we chose this
virus as an expression vector for RV G. A suitable live
recombinant RV vaccine must fulfill the following criteria: (i)
ability to produce high virus titers in tissue cultures; (ii) stable
expression of a correctly folded and processed RV G atFig. 3. Single-step virus growth curves of recombinant CAV2-RV G and wild-
type CAV2 in MDCK cells. MDCK cells were infected with CAV2-RV G or
CAV2 at m.o.i. of 1 and incubated at 34 °C. At the indicated times after
infection, viruses were harvested and titrated. Data are the mean (±SE) of 4 virus
titer determinations.
Fig. 4. Fluorescence microscopy analysis of RV G protein (green; B, E, H) and CAV2 proteins (red, C, F, I) in uninfected MDCK cells (G–I), CAV2-infected MDCK
cells (D–F), and CAV2-RV G-infected (A–C) MDCK cells at 48 h p.i. Panels A, D and G show bright-field microscopy results.
Fig. 5. Immunoprecipitation/Western blot analysis of the RV G produced in
MDCK cells infected with V-RG or CAV2-RV G. Infected cells were lysed and
subjected to immunoadsorption using a monoclonal antibody against the RV G.
Adsorbed proteins were separated by SDS-PAGE, transferred to nitrocellulose
membrane, and incubated with polyclonal rabbit antibody against RVG
followed by an Alexa Fluor 555-anti-rabbit IgG RV G. Bands were detected
using a molecular imager.
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ability to induce protective immunity after i.m. and especially
after i.n. and oral immunization. With respect to virus
replication, the CAV2-RVG produces virus titers in MDCK
cells similar to those produced by the wild-type CAV2,
indicating that the RVG gene does not affect virus replication.
However, these virus titers may be too low to meet the quality
requirements for an oral vaccine. Thus, efforts must be madeFig. 6. Cell surface expression of RV G onMDCK cells. Cells were either mock-
infected (solid histogram) or infected with CAV2 (black histogram), CAV2-RV
G (red histogram), or V-RG (green histogram) at a m.o.i. of 1 for 48 h and
incubated with recombinant human anti-RV G monoclonal antibody followed
by FITC-conjugated anti-human IgG. Surface expression was determined by
flow cytometry. Cells infected with CAV2-RV G showed RV G expression
levels comparable to those seen in V-RG-infected cells.
Table 1
Immunogenicity and protection in mice immunized i.m. or i.n with CAV2-RV G
Vaccination a VNA GMT [IU] (range) Survivorship b
Route Concentration [FFU]
i.m. 108 47.5 (1.7–324) 9/10
i.m. 107 6.7 (0.1–108) 9/10
i.m. 106 0.3 (0.1–12) 4/10
i.n. 107 12.8 (0.1–324) 7/10
i.n. 106 0.6 (0.1–108) 6/10
i.n. 105 2.0 (0.1–36) 6/10
Control 0 1/10
a Mice were vaccinated with 100 μl i.m. or 10 μl i.n.
b Mice were challenged i.m. with 10 LD50 of CVS-N2c and observed daily
for 4 weeks.
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replicating CAV2-RV G variants or by using bioreactor cell
culture technology as demonstrated for the production of
recombinant RVs (Dietzschold et al., 2004).
One of the most important determinants of the potency of a
live rabies vaccine vector is its capacity to express the RV G. In
this respect, vaccinia virus (Kieny et al., 1984) and rabies virus
(Faber et al., 2002) are excellent vectors that express the RV G
at very high levels. Comparison of RV G expressed by CAV2-
RV G with that of V-RG revealed similar expression levels,
suggesting that the potency of the CAV2-RV G vaccine is
comparable to that of the V-RG vaccine.
CAV2-RV G showed no safety-related problems in mice that
were immunized in this study. There were no clinical signs or
discomfort regardless of the amount of virus or the route of
administration. This observation promises to make CAV2-RV G
a safe vaccine for use in stray dogs and wild life, with only a
remote risk for humans. Nevertheless, the safety of CAV2-RV G
must be assessed in target and non-target animals before it can
be used in the field.
The other essential requirement for any live rabies vaccine is
high efficacy, which is particularly critical when the vaccine is
administered orally via vaccine-loaded baits and complete
delivery of the vaccine dose cannot be guaranteed. Immuniza-
tion of mice with CAV2-RV G by the i.m. or i.n. route induced
rabies VNA and conferred protection against a lethal RV
challenge infection in a dose-dependent manner; however,
VNA titers and survivorship decreased sharply when fewer
virus particles were administered. The sharp dose-dependent
decrease in the immune response, which was not observed after
immunization of mice with live recombinant RV (Faber et al.,
2002), could rest in the relatively low susceptibility of mouse
tissue to CAV2 infection, thereby limiting the virus spread and
preventing the generation of sufficient antigenic mass to mount
a protective immune response. This possibility is supported by
the observation that neither CAV2 nor CAV2-RVG infects
mouse neuroblastoma cells in vitro. The lack of sufficient
susceptibility of mice to the CAV2 virus points to the need for
future efficacy testing of CAV2-RV G in relevant animal target
species such as canines. Furthermore, the use of other animal
species for efficacy testing of orally administered CAV2-RV G
vaccines is especially important because it is for unknownreason difficult to immunize mice by the oral route regardless
of the vaccine used for immunization. On the other hand, most
of the modified-live RV vaccines, recombinant RV vaccines,
and also the modified-live CAV2 vaccine are effective in foxes
and raccoons after oral administration (Baer et al., 1989;
Sumner et al., 1988). The i.n. route was chosen for the
immunization of mice mainly for proof of principal that
protective immunity can be achieved by targeting mucosal
surface membranes. Although oral immunization with CAV2-
RV G did not confer protection against a lethal RV infection in
mice (data not shown), a strong immune response observed
after i.n. administration of CAV2-RVG is reason for optimism
that this vaccine will actually work by the oral route in
carnivores.
A crucial criterion for the efficacy of the CAV2-RVG is a low
natural prevalence of CAV2 in the population to be vaccinated.
In this regard, CAV2 is widespread among young dogs (Baker
et al., 1961) and naturally occurring antibody to CAV2 has been
detected in skunks, raccoons, foxes, and mongoose trapped in
the field (Sumner et al., 1988). However, it has also been
demonstrated that animals vaccinated orally with CAV2 had
marked antibody increases, even when they already had high
antibody titers to CAV2 (Sumner et al., 1988), suggesting that
oral administration of CAV2-RVG can overcome the preexist-
ing immunity to CAV2.Material and methods
Virus culture and cells
The Manhattan strain of CAV2 (kindly provided by the
Animal and Plant Health Inspection Service Center for
Veterinary Biologics, Ames, IA) was grown in MDCK cells
(ATCC, Manassas, VA) cultured in DMEM supplemented with
10% FBS, penicillin (50 U/ml) and streptomycin (50 U/ml). The
V-RG was obtained from our virus collection at Thomas
Jefferson University.
Virus titration
To determine virus yields, monolayers of MDCK cells in
96-well plates were infected with serial 10-fold dilutions of
CAV2 or CAV2-RVG as described (Wiktor et al., 1977). At
48 h post-infection (p.i.), cells were fixed in 4% paraformalde-
hyde in PBS, pH 7.4, incubated with a rabbit anti-RVG
polyclonal antibody (1:1000), and stained with FITC-labeled
goat anti-rabbit antibody (1:500, MP Biomedical, Aurora, OH).
Foci were counted using a fluorescence microscope and virus
titers calculated in focus-forming units (FFU). All titrations
were determined in triplicate.
Virus DNA purification
CAV2 was grown in MDCK cells for 5 days as described
above and concentrated by ultracentrifugation and purified by
sucrose gradient centrifugation. Viral DNA was isolated using
152 J. Li et al. / Virology 356 (2006) 147–154the DNeasy Tissue Kit (Qiagen, Valencia, CA) according to the
manufacturer's recommendation.
Cloning and sequencing of the CAV2 E3 DNA fragment
The CAV2 E3 region, which is not essential for virus
replication (Fischer et al., 2002), was used to introduce RVG
sequence from the SAD B19 RV strain into the CAV2 genome.
After sequencing the entire E3 region (including the protein
VIII precursor region and a 5′ region of fiber protein
sequence), a 3.0-kbp E3 DNA fragment was PCR-amplified
using high-fidelity DNA polymerase (Deep Vent, New
England BioLabs, Beverly, MA), isolated CAV2 DNA as
template, and primers F1 (TGTCAAGGACTCGAGTCCGG-
CACAGACT) and F2 (TACTATCCGCGGACAGCTTG-
CAACTGTTCGTTAATCA). The amplified fragment was
cloned into the vector pBluescript II SK(+) (Stratagene, La
Jolla, CA), resulting in pCAV2-E3.1. The correct sequence of
the cloned DNA fragment was verified by DNA sequencing.
Generation of a CAV2 expression cassette
PCR was used to amplify a truncated fragment from
pCAV2-E3.1 (1.2 kb deleted) with primers F3 (TACTAG-
TACCGGTTTGGTAAGAGTCTGGAATATCA) and F4
(CATCTAGCGTACGAAGAAGACACTCCAATTTTAAT),
which resemble the terminal 3′ and 5′ sequences of CAV2-E3,
and using unique restriction sites AgeI and BsiWI. The
amplified product was designated P1.
A second PCR was used to amplify the human CMV
promoter and the BGH polyadenylation sequence from plasmid
pcDNA3.1(+) (Invitrogen, Carlsbad, CA) using primers F5
(TACTAGTACCGGTCGTTGACATTGATTATTGACTAG)
and F6 (CATCTAGCGTACGCCATAGAGCCCACCG-
CATCCCCA). The product P2 was ligated with P1, resulting
in pCAV2-E3.2.
The RV G gene was introduced into pCAV2-E3.2 by the
addition of an EcoRI restriction site and Kozak translation
initiation sequence to the 5′ end and a PstI restriction site at
the 3′ end of the RV G gene using PCR and primers F7
(TAGTCCGGAATTCAAGATGGTTCCTCAGGCTCTCCTG)
and F8 (TGCACTGCAGTTATTACAGTCTGGTCT-
CACCCCCA). The amplified product, P3, was ligated to
pCAV2-E3.2 previously digested with EcoRI and PstI, resulting
in pCAV2-E3.3.
The plasmid pCAV2-GFP was constructed by the same
strategy using primers GFPf (TAGTCCGGAATTCGC-
CATGGGCGTGATCAAGCCCGACATGAAGATC) and
GFPr (TGCACTGCAGTTATTAGCCGGCCTGGCGGGG
TAGTCCGCTGTG).Generation of a recombinant CAV2-GFP virus by homologous
recombination
A recombinant CAV2-GFP was generated by transfecting
CAV2 DNA together with pCAV2-GFP into MDCK cells,picking up the green fluorescent foci detected in the transfected
cell monolayers, and performing five cycles of plaque purifica-
tion, resulting in a homogeneous CAV2-GFP population.Generation of recombinant CAV2-RV-G virus by homologous
recombination
pCAV2-E3.3 was extracted using the EndoFree Plasmid kit
(Qiagen), digested with AlwNI, and purified using QIAquick
PCR purification kit (Qiagen). Linearized pCAV2-E3.3 frag-
ment was transfected together with CAV2-GFP DNA using
Lipofectamine 2000 CD (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions. Briefly, the CAV2-GFP
DNA/pCAV2-E3.3 fragment/liposome mix was transfected into
MDCK cells, and plaques were transferred to nitrocellulose
filters and then to replica filters. The original filters were
hybridized with a specific RV G DNA probe to identify
recombinant CAV2-RV G virus-containing foci. After retrieval
from the replica filter, the virus was used to infect monolayers of
MDCK cells. Three days after infection, the tissue culture
supernatant was removed, the virus was transferred from the
infected cells to nitrocellulose filter and then to replica filter,
and CAV2-RV G containing foci were identified in situ as
described above. In addition, the supernatant from each culture
was subjected to PCR to determine the presence of RV G and
GFP DNA. This process was repeated until only RV GDNA but
no GFP DNA could be detected in the supernatant of the
infected cells.Immunofluorescence analysis
To analyze cell surface expression of RV G, MDCK cells
were infected with CAV2, CAV2-RV G, or V-RG at an m.o.i. of
1, and at 48 h p.i., infected cells were fixed with 4%
paraformaldehyde for 20 min at room temperature and treated
with 0.1% Triton-X100. After washing 3 times with PBS, cells
were incubated with RVG-specific rabbit antiserum (1:2000),
followed by Alexa Fluor 488-conjugated anti-rabbit IgG
(1;1000, Molecular Probes). Surface expression of G was
determined using a fluorescence microscope.Immunoprecipitation/Western blot analysis
MDCK cells were grown in T25 tissue culture flasks and
infected with CAV2-RVG, CAV2, or V-RG at a m.o.i. of 5,
incubated for 48 h at 37 °C, and lysed with lysis buffer (10 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X100, 0.5%
sodium deoxycholate). The lysate (500 μl) was mixed with
50 μl of recombinant human anti-RV G monoclonal antibody
SO57 (Prosniak et al., 2003), immobilized on Affi-Gel 10 (Bio-
Rad Laboratories, Hercules, CA), and incubated overnight with
agitation at 4 °C. After washing the immobilized antibody/
antigen complexes with lysis buffer, protein was eluted with
50 μl 0.1 M of diethanolamine and resolved by sodium dodecyl
153J. Li et al. / Virology 356 (2006) 147–154sulfate–10% polyacrylamide gel electrophoresis. The separated
proteins were transferred onto a nitrocellulose membrane,
incubated with a polyclonal rabbit antibody against RV G
followed by an Alexa Fluor 555-conjugated anti-rabbit IgG
(Molecular Probes). RV G bands were detected using a
molecular imager (FX Pro Plus; Bio-Rad, Hercules, CA).Flow cytometry
MDCK cells were infected with CAV2-RV G or V-RG at a
m.o.i. of 1 and incubated for 48 h at 34 °C. Cells were
suspended in PBS containing 50 mM EDTA, pelleted at 130×g
for 5 min, resuspended in 50 μl of PBS, and fixed in suspension
by addition of 500 μl of 4% paraformaldehyde solution. After
20 min, cells were washed twice with PBS containing 10 mM
glycine and 1% bovine serum albumin and incubated with
recombinant human anti-RVG monoclonal antibody SO57
(1:4000) followed by a FITC-conjugated affinity-purified goat
anti-rabbit antibody (1:500; MP Biomedical, Aurora, OH).
Flow cytometry was performed on an EPICS profile analyzer.Assessment of the protective activity of recombinant viruses
Groups of 10 female Swiss Webster mice (6-week-old) were
immunized i.m. with 100 μl or i.n. with 10 μl of 10-fold serial
dilutions of the recombinant virus in PBS. Thirty-two days after
immunization, the mice were challenged i.m. with 10 LD50 of
CVS-N2c challenge virus (Morimoto et al., 1998), and observed
daily for 4 weeks for clinical signs of rabies.Virus neutralization assay
At 25 days after immunization of mice, blood was collected
from the retroorbital sinus, sera were heat inactivated at 65 °C
for 30 min, and the RV-neutralizing activity was determined as
described (Wiktor et al., 1984a). The virus-neutralizing anti-
body (VNA) titers were transformed into international units
(IU) using the WHO anti-rabies virus antibody standard, and the
VNA geometric mean titer (GMT) was calculated for each
experimental group.Acknowledgments
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